Artelo Biosciences (ARTL) Accumulated Expenses (2017 - 2025)
Artelo Biosciences (ARTL) posted quarterly Accumulated Expenses of $11000.0 for Q4 2025, down 76.09% quarter-over-quarter from $46000.0 in Q3 2025.
Artelo Biosciences (ARTL) Accumulated Expenses (2017 - 2025) Analysis & Trends
Artelo Biosciences (ARTL) has reported Accumulated Expenses for 5 consecutive years, with $11000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Accumulated Expenses changed N/A year-over-year to $11000.0; the TTM figure through Dec 2025 stood at $11000.0 (changed N/A YoY), while the FY2025 annual figure was $11000.0, changed N/A from the prior year.
- Accumulated Expenses declined to $11000.0 in Q4 2025 per ARTL's latest filing, from $46000.0 in the prior quarter.
- Across five years, Accumulated Expenses topped out at $583966.0 in Q1 2021 and bottomed at $11000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Artelo Biosciences | 107,735.40 | -492,264.60 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 11,000.00 |
| Sep 30, 2025 | 46,000.00 |
| Jun 30, 2025 | 18,000.00 |
| May 31, 2021 | 418,943.00 |
| Feb 28, 2021 | 583,966.00 |
| Nov 30, 2020 | 474,065.00 |
| Aug 31, 2020 | 490,218.00 |
| May 31, 2020 | 255,632.00 |
| Feb 29, 2020 | 431,914.00 |
| Nov 30, 2019 | 574,530.00 |
| Aug 31, 2019 | 348,863.00 |
| May 31, 2017 | 1,603.00 |
| Feb 28, 2017 | 847.00 |